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Epigenetics is being increasingly combined with
epidemiology to add mechanistic understanding to
associations observed between environmental, genetic
and stochastic factors and human disease phenotypes.
Currently, epigenetic epidemiological studies primarily
focus on exploring if and where the epigenome
(i.e. the overall epigenetic state of a cell) is influenced
by specific environmental exposures like prenatal nu-
trition,
1 sun exposure
2 and smoking.
3 In this issue of
the IJE, Nada Borghol et al.
4 report an association
between childhood social-economic status (SES) and
differential DNA methylation in adulthood. Low SES
may integrate diverse and heterogeneous environmen-
tal influences, and knowing which epigenetic changes
are associated with low SES may provide clues about
the biological processes underlying its health conse-
quences. The authors stress that their study is prelim-
inary. This statement is, in fact, to a greater or lesser
extent applicable to the entire first wave of studies
currently being published that likewise aim to dis-
cover associations between epigenetic variation mea-
sured on a genome-wide scale and environmental
exposures or disease phenotypes. When executing
such epigenome-wide association studies (EWASs),
5
every epigenetic epidemiologist is struggling with the
same biological, technical and methodological issues.
It is important to take these into consideration when
designing a study and interpreting the results. Let us
consider seven of those issues, taking the current
study on SES as a starting point.
We do not really know where
to look, or what to look for
Most epigenetic epidemiological studies focus on DNA
methylation for various practical and biological rea-
sons, neglecting other layers of the epigenome-like
histone modifications that are also likely to be im-
portant in influencing disease phenotypes. Our basic
understanding of the methylome (i.e. the whole of
DNA methylation marks on the genome) is in its
infancy, and we are still learning about the specific
localization of the features that, when differentially
methylated, regulate gene expression and are thus
relevant for epigenetic epidemiologists to study. The
current study, like many others, evaluated promoter
regions, in this case defined as 1000bp upstream to
74 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY250bp downstream of transcription start sites.
Although these features are often enriched for DNA
methylation marks influencing the expression of
genes, recent work suggests that other regions of
the methylome outside of promoters, including
inter-genic CpG island shores
6 and intra-genic CpG
islands,
7 may ultimately be more important for regu-
lating phenotypic variation.
For any differentially methylated region identified in
EWASs it will be important to demonstrate function-
ality. Promoter methylation in the current study was
integrated with public gene expression data and, as
expected, highly expressed genes were more com-
monly flanked by less methylated promoters and
vice versa. A limitation is that this observation is for
groups of promoters, whereas information is needed
about this relationship for individual promoters.
Mining the reference epigenomes and transcriptomes
that are being generated for different cell types under
the umbrella of initiatives such as the National Insti-
tutes of Health (NIH) Epigenomics Roadmap
8 and the
International Human Epigenome Consortium
9 may
contribute to such information. Additional in vitro
experiments will be required to evaluate the transcrip-
tional effects of differential DNA methylation at a
specific locus independent of its genomic context.
10
We have to rely on imperfect
technology
The good news is that recent advances in genomic tech-
nology mean that genome-scale studies of DNA methy-
lation across multiple samples are now feasible. In
practice, however, one has to compromise between
coverage and precision in epidemiological studies,
which likely incorporate a large number of samples. A
large (and growing) number of methods exist for as-
sessing DNA methylation both genome wide and at spe-
cificCpGsites,
11andoneproblem relatestoourinability
to compare results across studies that have used differ-
ent platforms. On the one hand there are methods such
as that used in the current study in which the methy-
latedportionofthegenomeiscapturedusingantibodies
against methylated DNA and subsequently quantified
using microarrays or next-generation sequencing.
These approaches can provide coverage across most of
thegenome andmaybeoptimallysuitedtodiscriminate
low from high methylation, but have lower reliability
for smaller differences and are biased by factors such as
CG density.
12,13 On the other hand, there are methods
based on the bisulphite conversion of DNA combined
with next-generation sequencing that provide higher
accuracy and single nucleotide resolution. Although
whole-genome bisulphite sequencing is currently un-
feasible to use across large epidemiological cohorts,
the method can be adapted to target a reduced repre-
sentation of the genome(approximately3millionout of
approximately 28 million CG dinucleotides in the
human genome).
12,13 The recently launched Illumina
450k Methylation Beadchip may offer a balance be-
tween coverage and precision, which will be attractive
for epidemiological EWASs executed during the next
few years.
5 It interrogates DNA methylation at over
480000 CG dinucleotides, is high-throughput and rela-
tively affordable. The precision of this platform appears
to compare well with some of the other platforms,
12,13
but these results should be interpreted with caution.
Although correlation coefficients reported across the
various platform comparisons are high, they are
mainly driven by the fact that the large majority of the
genome is either unmethylated or fully methylated, and
substantial discrepancies between platforms may exist
for intermediate level methylation.
12,14 Therefore, the
technological validation of findings using an independ-
ent method remains important. This will be feasible
for a small number of ‘top hits’, like the three procad-
herinpromotersassessed inthecurrentstudy.However,
validating the outcomes of the complex pathway
analyses performed to implicate either entire biological
processes (such as extra- and intra-cellular signalling in
the current study) or genomic features with a specific
function in gene regulation [e.g. promoters, enhancers,
inter/intragenic CG island (shores) etc.], is more
demanding and currently not realized. Validating the
results of such gene-set testing methods will entail
the re-assessment of DNA methylation across large
sets of loci.
We may be limited by available
sample sizes that are optimal for
epigenetic epidemiology
The current study investigated only 40 individuals.
Investigators will be able to secure budgets for
larger studies as empirical data increasingly highlight
the value of epigenetic epidemiology, and high-
throughput, economical laboratory approaches
become more widely adopted. Nevertheless, it is un-
likely that the simple brute-force approach that has
been used relatively successfully in genome-wide as-
sociation studies (GWASs) is valid for EWASs. In gen-
etics, many of the epidemiological principles about
designing studies with respect to selection biases, con-
founding, batch effects and appropriateness of con-
trols could largely be replaced by the simple rule
‘bigger-is-better’. This is not true for epigenetic epi-
demiology, because the epigenome is not a static
entity like the genome, which necessitates the use
of more conventional epidemiological approaches.
15
Further complicating matters is the fact that, for the
most powerful study designs in epigenetic epidemi-
ology (including studies of discordant monozygotic
twins
16 particularly when longitudinally sampled,
17
early exposure studies with long-term follow-up,
1
and studies of specific cell types
18), the number of
eligible individuals for whom relevant biological
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horts were often limited, and it will be difficult to
scale-up analyses to include the thousands of samples
that may be required for establishing robust associ-
ations with disease phenotypes. Moving forward, it
will be important to establish cause and effect in epi-
genetic epidemiology; disease-associated differentially
methylated regions may arise prior to illness and con-
tribute to the disease phenotype or could be a second-
ary effect of the disease process, or the medications
used in treatment.
19 Furthermore, maximum infor-
mation will be obtained from epidemiological studies
that are able to integrate epigenomic information
with genomic, transcriptomic and proteomic data ob-
tained from the same samples.
Whatever we do, it may never
be enough to fully account for
epigenetic differences between
tissues and cells
In many respects, large comprehensively phenotyped
and longitudinally sampled epidemiological studies,
like the 1958 British birth cohort used in the current
study, are an ideal resource for epigenetic epidemi-
ology. In nearly all of these studies, however, whole
blood is the only biological material that has been
archived. Blood is a heterogeneous tissue and any
DNA methylation difference between groups could
be confounded by differences in the cellular compos-
ition of whole blood samples, for example, resulting
from the immune response to sub-clinical infection.
The good news is that fewer than perhaps expected
DNA methylation differences exist between leucocyte
types, and controlling for cellular heterogeneity may
be possible in biobanks with a simple blood cell
count.
20 Whether the latter is sufficient (and under
which circumstances it is not), however, remains to
be established. Epigenomic studies of separate cell
types such as those being undertaken by the NIH
Epigenomic Roadmap Initiative and the European
Union Blueprint consortium are currently generating
reference epigenomes of haematopoietic cells that will
be of great utility in this regard.
8 When moving
beyond associations with environmental exposures
to epigenetic associations with phenotypes, a key
question for epigenetic epidemiology concerns the
extent to which easily accessible peripheral tissues
(such as blood) can be used to ask questions about
inter-individual phenotypic variation manifest in in-
accessible tissues such as the brain, visceral fat and
other internal organs and tissues. Cross-tissue com-
parisons of the methylome within the same individual
are currently underway to establish the relationship
between epigenetic patterns in blood with other tis-
sues. Although these analyses are crucial, the results
may not be generally applicable; higher inter-tissue
concordance may be present for DNA methylation
changes induced early in development (and potential-
ly propagated soma-wide) than for changes occur
during ageing that are more likely to remain tissue
specific.
19,21 Efforts to obtain biopsies (subcutaneous
fat, muscle, etc.) and post-mortem material in subsets
of longitudinal biobanks will greatly increase their
value for epigenetic studies, despite the problems
associated with cellular heterogeneity that also hold
for such samples.
We may be trying to detect
inherently small effect sizes using
these sub-optimal methods and
sample cohorts
The main findings in the current study concerned
DNA methylation differences at three procadherin
promoters.
4 The extent of the difference at these pro-
moters was similar to those commonly observed in
other recent studies, namely  5%,
5 and was most ap-
parent for a single, nominally statistically significant
CG dinucleotide in each region. The biological impli-
cations of such small alterations in DNA methylation
in terms of gene expression and function are un-
known. Although DNA methylation is recognized as
one of the most stable epigenetic marks, it is still
relatively dynamic and this has important implica-
tions for epigenetic epidemiology. The randomness
of maintaining and mitotically transmitting DNA
methylation patterns may potentially dilute the puta-
tive epigenetic signatures of an adverse exposure early
in life (e.g. to low SES in childhood) observed dec-
ades later. Of note, recent studies indicate that DNA
methylation patterns in leucocytes undergo consider-
able changes during the first years of life.
22 Thus on
top of the previously discussed question of whether
DNA methylation at a specific locus actually influ-
ences transcriptional activity, researchers should also
aim to establish whether the small DNA methylation
differences often observed between groups—either ex-
pressed as absolute difference, relative difference or
relative to the variation in the population—translate
into differences in gene expression in the relevant
tissue. It will be of particular interest to see whether
the effects of such modest differences, while perhaps
of little consequence individually, may shift transcrip-
tion of a biological process or functional network
when they co-occur with other changes to the
methylome.
23 Little is known about the actual scale
and extent of between-individual variation in DNA
methylation across the genome. In this regard,
public genome-scale resources need to be created
that document inter-individual differences in DNA
methylation and gene expression, in addition to the
reference epigenomes that are currently being
generated.
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analysis of genome-wide epigenetic
data
The results of GWASs are relatively easy to judge.
Quality-control steps are well-defined and reported,
individually testing every genetic variant [i.e. single
nucleotide polymorphism (SNP)] is straightforward,
and levels of genome-wide statistical significance are
clear. For EWASs, the analytical methodology is very
much under construction. For example, in the current
study it was not possible to attain genome-wide levels
of significance, which is acceptable for an exploratory
study, but makes it difficult to fully interpret the re-
ported differences. Because of the vast range of meth-
ods currently being used to assess DNA methylation,
meta-analyses across different studies are difficult.
The adoption of a common technology platform,
such as the new Illumina 450k Methylation
Beadchip, across multiple studies would provide an
excellent opportunity to converge on widely accepted
guidelines for the analysis and integration of EWAS
data. Apart from pre-processing procedures (quality
control, normalization, handling different probe
types, accounting for genetic variation, etc.), elements
of these guidelines should deal with the analysis of
individual CG dinucleotides vs groups of (correlated)
adjacent CGs, the use of genome annotations in the
analysis (histone states, promoter types, CG content,
etc.), and levels of epigenome-wide significance for
various analyses. An important aspect will be the ex-
ploration of the previously mentioned gene-set testing
methods in the context of DNA methylation since
they will be vital to obtain meaningful interpretations
of genome-wide data in terms of underlying biological
processes or genomic functions [e.g. promoters, en-
hancers, inter/intragenic CG island (shores), etc.].
For example, commonly used enrichment methods
assume independence within a gene set and, apart
from consistency in biological signal in a gene set,
statistical significance may reflect consistency in
other characteristics such as GC content, coverage or
other sequence features.
24 Alternative implementa-
tions of gene-set testing methods include global test-
ing approaches.
25 Finally, it will be important to adopt
an integrative paradigm based on the combination of
genetic and epigenetic epidemiological data.
26 Of par-
ticular relevance in this respect is evidence for the
widespread occurrence of allele-specific DNA methy-
lation (ASM) across the genome. Recent studies have
shown that there are considerable inter-individual dif-
ferences in ASM, which are frequently associated with
genetic variation but can also be mediated by genomic
imprinting (i.e. the parent-of-origin dependent silen-
cing of expression by epigenetic mechanisms), envir-
onmental influences and apparently stochastic factors
in the cell.
27,28 ASM can mask the effect of risk alleles
by silencing their expression, and also provides a po-
tential mechanism underlying gene–environment
interactions.
26 Furthermore, ASM may contribute to-
wards the apparent ‘missing heritability’ of many
complex diseases and the low penetrance often re-
ported for SNPs identified by GWASs.
29
We have to manage high
expectations
There is a considerable interest in epigenetic research
in the popular press. The current study is a vivid
illustration: even though the authors deem it prelim-
inary, it was widely covered by the media.
30
Epigenetics should avoid some of the hype that sur-
rounded the early days of genetic epidemiology. After
the draft human genome sequence was announced in
2001, it was widely perceived that we would soon
understand the causes of most common diseases
and how to treat them. This expectation was not real-
istic, but not always renounced by geneticists.
Currently, many scientists outside the field are disap-
pointed by results of human genetics, and in particu-
lar GWASs, despite their overall considerable success.
Genetic epidemiology has proven to be harder than
expected despite the favourable starting point of thou-
sands of Mendelian diseases and the high heritabil-
ities associated with most traits to be explained. Very
much like genetics, epigenetics will not be able to
deliver the miracles it is sometimes claimed it will.
In conclusion, epigenetic epidemiology is early in its
development and susceptible to new ideas and appro-
aches. Only a few years ago empirical papers were
greatly outnumbered by reviews. Now, reference epi-
genomes are produced at great pace (see http://epi-
genomeatlas.org).
8,9 Moreover, furthered by pilot
studies like the one from Nada Borghol et al.,
4 the
outline of the infrastructure required for EWASs is
emerging. Crucial elements include optimal study de-
signs, benchmarking technology and data analysis
approaches that are statistically and biologically
sound. An additional key aspect to the successful
design and interpretation of epigenetic epidemiologic-
al studies will be the creation of public genome-scale
resources focusing on inter-individual variation incor-
porating epigenomic, DNA sequence and transcrip-
tomic data. Education, hard work and a certain
degree of luck will get us there—not very different
to the remedy against low SES.
Funding
NGI/NWO (#93518027, to B.T.H.); NGI/NWO-funded
Netherlands Consortium for Healthy Ageing (NCHA)
(#05060810, B.T.H.); NIH grant (AG036039, to J.M.).
Acknowledgement
We thank Elmar Tobi for his comments.
THE SEVEN PLAGUES OF EPIGENETIC EPIDEMIOLOGY 77Conflict of interest: None declared.
References
1 Tobi EW, Lumey LH, Talens RP et al. DNA methylation
differences after exposure to prenatal famine are common
and timing- and sex-specific. Hum Mol Genet 2009;18:
4046–53.
2 Gronniger E, Weber B, Heil O et al. Aging and chronic sun
exposure cause distinct epigenetic changes in human
skin. PLoS Genet 2010;6:e1000971.
3 Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H.
Tobacco-smoking-related differential DNA methylation:
27K discovery and replication. Am J Hum Genet 2011;88:
450–57.
4 Borghol N, Suderman M, McArdle W et al. Associations
with early-life socio-economic position in adult DNA
methylation. Int J Epidemiol 2012;41:62–74.
5 Rakyan VK, Down TA, Balding DJ, Beck S. Epigenome-
wide association studies for common human diseases.
Nat Rev Genet 2011;12:529–41.
6 Irizarry RA, Ladd-Acosta C, Wen B et al. The human colon
cancer methylome shows similar hypo- and hypermethy-
lation at conserved tissue-specific CpG island shores. Nat
Genet 2009;41:178–86.
7 Deaton AM, Webb S, Kerr AR et al. Cell type-specific DNA
methylation at intragenic CpG islands in the immune
system. Genome Res 2011;21:1074–86.
8 Bernstein BE, Stamatoyannopoulos JA, Costello JF et al.
The NIH Roadmap Epigenomics Mapping Consortium.
Nat Biotechnol 2010;28:1045–8.
9 Anonymous. Moving AHEAD with an international
human epigenome project. Nature 2008;454:711–5.
10 Klug M, Rehli M. Functional analysis of promoter CpG
methylation using a CpG-free luciferase reporter vector.
Epigenetics 2006;1:127–30.
11 Laird PW. Principles and challenges of genomewide DNA
methylation analysis. Nat Rev Genet 2010;11:191–203.
12 Bock C, Tomazou EM, Brinkman AB et al. Quantitative
comparison of genome-wide DNA methylation mapping
technologies. Nat Biotechnol 2010;28:1106–14.
13 Harris RA, Wang T, Coarfa C et al. Comparison of
sequencing-based methods to profile DNA methylation
and identification of monoallelic epigenetic modifications.
Nat Biotechnol 2010;28:1097–105.
14 Sandoval J, Heyn HA, Moran S et al. Validation of a DNA
methylation microarray for 450,000 CpG sites in the
human genome. Epigenetics 2011;6:692–702.
15 Relton CL, Davey Smith G. Epigenetic epidemiology of
common complex disease: prospects for prediction, pre-
vention, and treatment. PLoS Med 2010;7:e1000356.
16 Dempster EL, Pidsley R, Schalkwyk LC et al.
Disease-associated epigenetic changes in monozygotic
twins discordant for schizophrenia and bipolar disorder.
Hum Mol Genet 2011. doi:10.1093/hmg/ddr416 [Epub 9
September 2011].
17 Wong CC, Caspi A, Williams B et al. A longitudinal
study of epigenetic variation in twins. Epigenetics 2010;5:
516–26.
18 Ollikainen M, Smith KR, Joo EJ et al. DNA methylation
analysis of multiple tissues from newborn twins reveals
both genetic and intrauterine components to variation in
the human neonatal epigenome. Hum Mol Genet 2010;19:
4176–88.
19 Heijmans BT, Tobi EW, Lumey LH, Slagboom PE. The
epigenome: archive of the prenatal environment.
Epigenetics 2009;4:526–31.
20 Talens RP, Boomsma DI, Tobi EW et al. Variation, pat-
terns, and temporal stability of DNA methylation: consid-
erations for epigenetic epidemiology. FASEB J 2010;24:
3135–44.
21 Thompson RF, Atzmon G, Gheorghe C et al.
Tissue-specific dysregulation of DNA methylation in
aging. Aging Cell 2010;9:506–18.
22 Martino DJ, Tulic MK, Gordon L et al. Evidence for
age-related and individual-specific changes in DNA
methylation profile of mononuclear cells during early
immune development in humans. Epigenetics 2011;6:
1085–94.
23 Stoger R. The thrifty epigenotype: an acquired and herit-
able predisposition for obesity and diabetes? Bioessays
2008;30:156–66.
24 Goeman JJ, Buhlmann P. Analyzing gene expression data
in terms of gene sets: methodological issues. Bioinformatics
2007;23:980–87.
25 Goeman JJ, van de Geer SA, de Kort F, van
Houwelingen HC. A global test for groups of genes: test-
ing association with a clinical outcome. Bioinformatics
2004;20:93–99.
26 Meaburn EL, Schalkwyk LC, Mill J. Allele-specific
methylation in the human genome: implications for
genetic studies of complex disease. Epigenetics 2010;5:
578–82.
27 Shoemaker R, Deng J, Wang W, Zhang K. Allele-specific
methylation is prevalent and is contributed by CpG-SNPs
in the human genome. Genome Res 2010;20:883–89.
28 Schalkwyk LC, Meaburn EL, Smith R et al. Allelic skewing
of DNA methylation is widespread across the genome. Am
J Hum Genet 2010;86:196–212.
29 Kong A, Steinthorsdottir V, Masson G et al. Parental
origin of sequence variants associated with complex dis-
eases. Nature 2009;462:868–74.
30 Coghlan A. Childhood poverty leaves its marks on
adult genetics. New Scientist 2011. [Epub 26
October 2011]; http://www.newscientist.com/article/
dn20255-childhood-poverty-leaves-its-mark-on-adult-
genetics.html (15 November 2011, date last accessed).
78 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY